Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0699790 (
colon cancer
)
28,837
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2) is one of the master regulators that control hundreds of genes containing antioxidant response elements (AREs). The NRF2-ARE pathway plays a complex role in colorectal cancer (CRC). NRF2 activity is known to be regulated by KEAP1-CUL3 E3 ligase-mediated ubiquitination, indicating the importance of deubiquitination regulation. However, the deubiquitinase (DUB) of NRF2 remains unknown. Here, by screening a DUB library, we identified
DUB3
as a DUB that remarkably stabilized NRF2. Further experiments demonstrated that
DUB3
promoted NRF2 stability and transcriptional activity by decreasing the K48-linked ubiquitination of NRF2. Coimmunoprecipitation studies revealed interactions between NRF2 and
DUB3
, as well as between KEAP1 and
DUB3
, indicating that NRF2,
DUB3
, and KEAP1 formed a large functional complex. Importantly, ectopic expression of
DUB3
caused NRF2-dependent chemotherapy resistance in
colon cancer
cell lines. Thus, to the best of our knowledge, our findings are the first to identify
DUB3
as a NRF2 DUB and may provide a new strategy against chemotherapy resistance in CRC and other NRF2-related diseases.
...
PMID:DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer. 3077